Taselisib

Taselisib

Taselisib

Chemical compound

Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA).[1][2]

Quick Facts Clinical data, ATC code ...

Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study.[3] Currently running clinical trials[4] were continued for patients exhibiting benefit.

References

  1. [1]
    "Definition of taselisib - NCI Drug Dictionary - National Cancer Institute". Cancer.gov. Retrieved 2017-01-10.
  2. [2]
    Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, et al. (April 2016). "Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations". Clinical Cancer Research. 22 (8): 2009–19. doi:10.1158/1078-0432.CCR-15-2245. PMC 4870591. PMID 26589432.
  3. [3]
    "Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer".
  4. [4]
    https://clinicaltrials.gov/ct2/results?term=taselisib&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Taselisib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.